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Abstract
Background: We studied the oxidation of
an oil rich in docosahexaenoic acid (DHA;
DHASCO®) in lactating mothers receiving a
dietary DHA supplement or a placebo. The
results were compared with the oxidation of
linoleic acid. Methods: Breast-feeding moth-
ers received a dietary supplement (DHASCO;
200 mg DHA/day, n = 5) or a placebo (n = 5)
for 14 days. Six weeks post partum all 10
mothers received a single dose of 2 mg/kg
body weight uniformly 13C-labeled DHASCO.
In a previously reported study 6 mothers
received 1 mg/kg body weight uniformly 13C-
labeled linoleic acid. Breath samples were
collected over 48 h after tracer application.
The total CO2 production was measured by
indirect calorimetry and the 13C isotopic en-
richment of labeled CO2 by isotopic ratio
mass spectrometry. Results: The oxidation of
13C-labeled DHASCO in the supplemented
and placebo groups was similar. Maximal 13C
enrichment was reached earlier in the group
receiving 13C-DHASCO (median 1.0 vs. 3.0 h
in the linoleic acid group). The cumulative 13C
recovery in breath was higher in the DHAS-
CO versus the linoleic acid group until 10 h
after tracer application and comparable
thereafter. Conclusions: The difference in ox-
idation of DHASCO versus linoleic acid after
tracer ingestion might be partly due to a fas-
ter absorption and oxidation of shorter chain
saturated fatty acids contained in DHASCO.
The cumulative oxidation of DHASCO and
linoleic acid 24 and 48 h after tracer ingestion
is similar.
Copyright © 2000 S. Karger AG, Basel
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Introduction
The supply of essential fatty acids and
long-chain polyunsaturated fatty acids (LCP)
is important for normal growth and develop-
ment of infants. Their contents in human
milk depend on maternal nutrition, utiliza-
tion, and composition of depot fats and en-
dogenous LCP synthesis from precursors [1–
3]. Essential fatty acids and LCP may also be
used as an energy source and thus be oxidized
to CO2. Methods for measuring the in vivo
oxidation of substrates labeled with the non-
radioactive isotope 13C have been increasing-
ly used for diagnostic and research purposes
[4–6]. Small excesses of exogenous 13CO2 aris-
ing from oxidation of the labeled substrate
can be measured by sensitive mass spectrome-
try techniques [5, 6].
The first objective of this study was to
investigate the oxidation of an orally applied
13C-labeled oil rich in docosahexaenoic acid
(DHA; DHASCO®, Martek Biosciences, Co-
lumbia, Md., USA) in a group of lactating
mothers supplemented either with DHA or a
placebo oil. The second objective was to com-
pare the oxidation of this fatty acid mixture
containing about 40% DHA with the oxida-
tion of a single polyunsaturated fatty acid (lin-
oleic acid) in lactation.
Subjects and Methods
Ten healthy breast-feeding mothers were recruited
after term delivery at the Department of Gynecology
and Obstetrics, University of Munich. The study was
approved by the Ethical Committee of the Medical
Faculty of the University of Munich, and written con-
sent was obtained from the participating women.
The women were 31 B (SD) 5 years old and had a
weight of 71.4 B 4.6 kg (at 4 weeks post partum) and a
height of 170 B 6 cm. All were consuming omnivorous
diets which were assessed by 7-day weighted dietary
protocols. At 4 weeks post partum (study day 0), they
were randomly and blindly assigned to receive either a
Table 1. Fatty acid composition (w%) of the capsules
with the dietary supplement DHASCO oil, the 13C-
labeled DHASCO oil, and the placebo capsules con-
taining a 1:1 mixture of corn and soy oils
Fatty acid DHASCO
capsulesa
13C-labeled
DHASCOa
Placebo
capsulesb
– 0.0–0.3 –
C10:0 – 1.1–1.8 –
C12:0 5.4 7.8–9.3 –
C14:0 19.40 18.1–19.6 –
C16:0 17.5 9.0–13.2 11.0
C18:0 0.4 0.0–0.3 3.0
C20:0 – 0.1 0.4
C16:1n-7 1.7 0.9–1.0 –
C18:1n-9 9.5 5.1–7.4 23.3
C20:1n-9 – 0.0–0.3 0.3
C18:2n-6 0.6 – 56.7
C18:3n-3 – – 4.1
C22:5n-3 0.3 0.2–0.4 –
C22:6n-3 45.1 49.3–55.4 –
C24:1n-9 – – –
a Analysis in our laboratory (analysis of 13C tracer
represents the range from three different lots).
b Compositional data provided by the manufac-
turer.
dietary supplement rich in DHA (200 mg DHA/day
from DHASCO capsules) or a placebo oil for 14 days.
The mothers were asked not to eat fish (rich in n-3
LCP) during the 2-week supplementation period. Fur-
ther, they were asked not to eat corn-based products
the day before tracer application because of an ele-
vated 13C content. At 6 weeks post partum mothers
from both groups received with their breakfast a single
dose of 2 mg/kg of uniformly 13C-labeled DHASCO oil
(57.1–65.7% 13C enrichment). The fatty acid composi-
tions of the DHASCO and placebo capsules as well as
the tracer are shown in table 1. In a previously pub-
lished comparable study [1], 6 breast-feeding mothers
(age 31 B 3 years, weight 68.17 B 8.2 kg, height 167 B
3 cm; mean B SD) received a single dose of uniformly
13C-labeled linoleic acid (F98% 13C labeling; Martek
Biosciences) at 6 weeks post partum.
Exhaled breath samples were collected into 1-liter
breath bags. An aliquot of 11 ml was transferred into
evacuated glass tubes (Labco, Manchester, UK) and
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stored until measurement of the 13C content of the
CO2. Immediately before tracer application a breath
sample was taken in triplicate in order to measure
baseline 13C enrichment of CO2. Further samples were
collected 30 min and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24,
36, and 48 h after tracer administration. The total CO2
production was measured by indirect calorimetry
twice in each woman from 30 min preprandial until 30
min postprandial (Deltatrac® II MBM-200; Hoyer,
Bremen, Germany). The 13C enrichments of breath
CO2 were measured in duplicate by isotopic ratio mass
spectrometry (Delta S; Finnigan MAT, Bremen). Car-
bon isotope ratios were expressed as ‰ 13C values (‰)
versus the Pee Dee Belemnite standard. The oxidation
rates over 48 h were calculated as described elsewhere
[1].
Statistical differences between the DHA-supple-
mented group and the placebo group as well as between
the groups combined (supplemented and placebo
groups; n = 10) and the group given 13C linoleic acid
were assessed by a nonparametric test (Mann-Whit-
ney, Monte Carlo) using the Stastical Package for the
Social Sciences (version 8.0; SPSS, Chicago, Ill., USA).
This test was chosen due to the relatively small number
of subjects per group. The significance level was set at
p ! 0.05, and the results are presented as median and
interquartile range (IQR).
Results
The times of peak 13C enrichment in
breath CO2 (delta over baseline, DOB) of the
DHA-supplemented group and the placebo
group were at 1 h (1.0–1.0; median and IQR)
and at 2 h (1.0–3.3), respectively (table 2).
Forty-eight hours after tracer application 13C
enrichment in both groups had almost re-
turned to baseline values [DOB 0.21‰ (0.04–
0.59)]. Because of the nearly identical kinetics
of the supplemented and the placebo group,
both were combined for comparison with the
linoleic acid group.
Time of peak 13C enrichment in the com-
bined group was at 1 h (1.0–2.0) after tracer
application which was about 3 h earlier than
in the linoleic acid group [3.5 h (3.0–4.0); p =
0.003].
The percentage of the dose of tracer 13C
exhaled in CO2 per hour (percent dose recov-
ery; PDR/h) tended to be slightly higher dur-
ing the first 2 h after tracer application in the
DHA-supplemented versus the placebo group
which was not significantly different due to
large interindividual differences (fig. 1). From
3 to 48 h after tracer application, the tracer
oxidation did not differ between the supple-
mented and the placebo groups.
A comparison of the combined group and
the linoleic acid group showed a severalfold
higher PDR/h in the group receiving labeled
DHASCO during the first 4 h after tracer
application: 18-fold higher at 1 h after tracer
ingestion, 7-fold higher at 2 h, 3.4-fold higher
at 3 h, and 1.6-fold higher at 4 h (fig. 2). At the
later time points, 5–24 h after tracer applica-
tion, there were no significant differences be-
tween the combined and the linoleic acid
group. At 30 and 48 h after tracer application,
the PDR/h in the linoleic acid group versus
the combined group was higher [30 h: 0.22
(0.17–0.28) vs. 0.13 (0.08–0.15), p = 0.003;
48 h: 0.20 (0.12–0.25) vs. 0.05 (0.03–0.08),
p = 0.026; see figure 2).
The cumulative PDR/h of tracer doses in
breath tended to be higher in the DHA-sup-
plemented group than in the placebo group
during the first 2 h after tracer application.
This difference was significant only at 1 h
after the tracer application [1.61% (1.38–
1.77) in the supplemented vs. 0.76% (0.40–
1.15) in the placebo group, p = 0.033].
The cumulative recovery of 13C in the
combined group at 1 h after tracer ingestion
was 10.7-fold higher than in the linoleic acid
group (1.28 vs. 0.12). This tendency was ob-
served during the first 10 h after tracer appli-
cation. From 24 to 48 h after tracer applica-
tion, the cumulative recovery of DHASCO
and linoleic acid was very similar and reached
about 15% of the ingested doses (fig. 3).
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Fig. 1. Time course of 13C in breath CO2 in breast-feeding mothers receiving DHA supple-
mentation (n = 5) or a placebo (n = 5) after oral application of 2 mg/kg body weight of
U-13C-labeled DHASCO, expressed as percentage of tracer dose ingested per hour (PDR/h).
Median and IQR.
Fig. 2. Time course of 13C in breath CO2 in breast-feeding mothers after oral tracer applica-
tion of 13C-DHASCO (n = 10) or 13C-linoleic acid (n = 6) [1]. Median and IQR. * p ! 0.05;
** p ! 0.01.
1
2
Time point of ‰13C peak (h after administration)
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Fig. 3. Time course of cumulative recovery of 13C in breath CO2 in breast-feeding mothers
after oral tracer application of 13C-DHASCO (n = 10) or 13C-linoleic acid (n = 6) [1]. Median
and IQR. * p ! 0.05; ** p ! 0.01; *** p ! 0.001.
Table 2. Time point of ‰13C peak
and peak ‰13C values (‰) in
breath CO2 of lactating women
after oral administration of
13C-DHASCO and 13C-linoleic
acid [1] at 6 weeks post partum
Supplement DHASCO
13C-DHASCO
(n = 5)
subject No. h
Placebo
13C-DHASCO
(n = 5)
subject No. h
Regular diet
13C-linoleic acid
(n = 6)
subject No. h
1 1 6 1 11 3
2 1 7 1 12 4
3 1 8 2 13 5
4 1 9 3 14 3
5 1 10 4 15 3
Peak ‰13C value, ‰
1 22.47 6 22.47 11 9.95
2 29.04 7 19.14 12 8.00
3 24.88 8 17.79 13 5.95
4 22.18 9 17.62 14 8.00
5 20.01 10 15.80 15 10.20
16 13.10
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Discussion
In this study, we investigated the oxidation
of an oil rich in DHA and compared these
results with data obtained in a previous
study on linoleic acid oxidation in lactating
women.
DHASCO is a refined single-cell triglycer-
ide oil highly enriched in DHA that is pro-
duced by the microalgal strain MK 8805 [7].
Due to positional preference of DHA for sn-1
and sn-3, it is more similar to mammal than
to fish oil. It is used as a dietary supplement to
elevate the levels of DHA in conventional
foods, especially in infant formulas [7, 8].
DHASCO labeled with 13C, a safe nonra-
dioactive isotope that causes no radiation risk
to mother or infant [4, 9, 10], was used to
measure fatty acid oxidation. Breath tests us-
ing stable isotopic labeled substrates are gen-
erally considered as safe and noninvasive
tests to measure in vivo substrate oxidation
[6, 11–13].
The baseline 13C content in breath CO2 of
mothers from the combined group was 1.0838
atom percent (1.0837–1.0839; median and
IQR) and achieved peak 13C enrichment of
1.1051 atom percent (1.1027–1.1082) which
represents !2% enrichment over the baseline.
The baseline 13C content in breath CO2 mea-
sured in our study is slightly lower than the
natural average 13C abundance reported in
Europeans (1.088) [14]. This is a reflection of
the local Bavarian diet, with little intake of
maize and cane sugar, but high in proportions
of potato, cabbage, rice, and beet sugar, as
well as the overnight fasting.
Our results show no apparent difference
in the kinetics and the cumulative oxidation
rate between the groups of women that were
supplemented or not supplemented with
DHASCO over a period of 14 days. The direct
measurement of DHA oxidation was not in-
tended in this study. This would have only
been possible using a pure DHA tracer, in-
stead of a mixture of different fatty acids.
We combined the results of the DHA-sup-
plemented and the placebo groups and com-
pared the oxidation of a single oral dose of
13C-DHASCO with the results of the 13C-lin-
oleic acid oxidation obtained in a previous
study [1]. Time points of sampling exhaled air
and the measurement of 13C enrichment of
breath CO2 were performed in the same way
and using the same instruments as in the cur-
rent study.
Earlier maximum 13C enrichment in
breath CO2 (DOB) in the combined group
versus the linoleic acid group (1.0 vs. 3.5;
median) reflects the faster oxidation rate of
the DHASCO tracer. Different kinetics of the
oxidation of the two tracers can also be seen
from the data of the PDR/h (fig. 1) and the
cumulative recovery of the tracer in breath
(fig. 3).
The oxidation rate of DHASCO tracer ver-
sus linoleic acid was faster, especially during
the first 4 h after its ingestion. The 13C-labeled
DHASCO tracer is a triglyceride-oil mixture
that contains twelve different fatty acids, with
the main components being lauric (C12:0),
myristic (C14:0), and palmitic acid (C16:0)
and DHA (C22:6n-3) which represent 84.2–
97.5 w% of all the fatty acids (table 1). From
the oxidation data alone, it is difficult to spec-
ulate which fatty acids are the ones with faster
oxidation in DHASCO as compared with lin-
oleic acid. Cumulative 13C enrichments of
single fatty acids at 48 h in human milk of
mothers from the combined DHASCO group
were severalfold higher for C16:0, C16:1n-7,
C18:1n-9, and C22:6n-3 than for of C14:0
[unpubl. data]. This could be explained by a
greater rate of C14:0 oxidation in comparison
with other mono- and polyunsaturated fatty
acids contained in DHASCO. This preserva-
tion from oxidation is in agreement with the
results of a study performed by Metges and
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Wolfram [15] who found greater and more
rapid oxidation of trioctanoate as compared
with trioleate after oral and parenteral admin-
istration in healthy adult volunteers.
It is likely that the faster oxidation rate of
DHASCO, as compared to linoleic acid, is
due to a quicker absorption and oxidation of
shorter-chain saturated fatty acids (C8:0,
C10:0, C12:0, and C14:0) contained in
DHASCO. The cumulative oxidation of
DHASCO is about 15% of the dose at 48 h
after ingestion. This value is comparable to
values obtained in other studies measuring
fatty acid oxidation. Although there were dif-
ferences in the kinetics of oxidation between
the DHASCO group and the linoleic acid
group, the cumulative oxidation 1 and 2 days
after tracer application did not differ.
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